MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wajant, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wajant, H.
Molecular Interventions 3:124-127 (2003)
© 2003 American Society of Pharmacology and Experimental Therapeutics



Viewpoint

Targeting the FLICE Inhibitory Protein (FLIP) in Cancer Therapy

Harald Wajant

Department of Molecular Medicine Medical Polyclinic, University of Wuerzburg Roentgenring 11, 97070 Wuerzburg, Germany

SUMMARY

In some cases, treatment of ovarian cancer cells with tumor necrosis factor-{alpha} can induce an apoptotic signal leading to the death of these cells; however, many ovarian malignancies are resistant to the effects of TNF-{alpha}. A new publication describes how these ovarian tumors may evade death receptor-mediated apoptosis. Apparently, the extracellular signals transduced by death receptors (e.g., TNF receptors) are extinguished before the cascade of caspases, which proteolytically cleave other proteins, can be activated. Overexpression of FLIP, a protein that blocks the caspase activity of FLICE, mediates the observed resistance. Thus, FLIP, which normally prevents inappropriate apoptosis, may become a tumor progression factor. Strategies to overcome this FLIP-mediated blockade of programmed cell death in tumors might become useful for positive prognoses.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
S. M. Raja, S. Chen, P. Yue, T. M. Acker, B. Lefkove, J. L. Arbiser, F. R. Khuri, and S.-Y. Sun
The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis
Mol. Cancer Ther., July 1, 2008; 7(7): 2212 - 2223.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Y. Ding, K. J. Choi, J. H. Kim, X. Han, Y. Piao, J.-H. Jeong, W. Choe, I. Kang, J. Ha, H. J. Forman, et al.
Endogenous Hydrogen Peroxide Regulates Glutathione Redox via Nuclear Factor Erythroid 2-Related Factor 2 Downstream of Phosphatidylinositol 3-Kinase during Muscle Differentiation
Am. J. Pathol., June 1, 2008; 172(6): 1529 - 1541.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. A. Elrod, Y.-D. Lin, P. Yue, X. Wang, S. Lonial, F. R. Khuri, and S.-Y. Sun
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway
Mol. Cancer Ther., July 1, 2007; 6(7): 2029 - 2038.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Qiu, X. Liu, W. Zou, P. Yue, S. Lonial, F. R. Khuri, and S.-Y. Sun
The Farnesyltransferase Inhibitor R115777 Up-regulates the Expression of Death Receptor 5 and Enhances TRAIL-Induced Apoptosis in Human Lung Cancer Cells
Cancer Res., May 15, 2007; 67(10): 4973 - 4980.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Liu, P. Yue, S. Chen, L. Hu, S. Lonial, F. R. Khuri, and S.-Y. Sun
The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells
Cancer Res., May 15, 2007; 67(10): 4981 - 4988.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Liu, P. Yue, A. H. Schonthal, F. R. Khuri, and S.-Y. Sun
Cellular FLICE-Inhibitory Protein Down-regulation Contributes to Celecoxib-Induced Apoptosis in Human Lung Cancer Cells
Cancer Res., December 1, 2006; 66(23): 11115 - 11119.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Y. Chen, J. Xu, N. Jhala, P. Pawar, Z. B. Zhu, L. Ma, C.-H. Byon, and J. M. McDonald
Fas-Mediated Apoptosis in Cholangiocarcinoma Cells Is Enhanced by 3,3'-Diindolylmethane through Inhibition of AKT Signaling and FLICE-Like Inhibitory Protein
Am. J. Pathol., November 1, 2006; 169(5): 1833 - 1842.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Cai, C. Stoicov, H. Li, J. Carlson, M. Whary, J. G. Fox, and J. Houghton
Overcoming Fas-Mediated Apoptosis Accelerates Helicobacter-Induced Gastric Cancer in Mice
Cancer Res., December 1, 2005; 65(23): 10912 - 10920.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Jin, X. Liu, Z. Zhou, P. Yue, R. Lotan, F. R. Khuri, L. W.K. Chung, and S.-Y. Sun
Activation of Nuclear Factor-{kappa}B Contributes to Induction of Death Receptors and Apoptosis by the Synthetic Retinoid CD437 in DU145 Human Prostate Cancer Cells
Cancer Res., July 15, 2005; 65(14): 6354 - 6363.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.